🇺🇸 FDA
Pipeline program

HCD122

CHCD122A2103

Phase 2 small_molecule completed

Quick answer

HCD122 for Non-Hodgkin's Lymphoma is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Non-Hodgkin's Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials